| Date | Title | Description |
| 02.09.2026 | Top US doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion | Getting your Trinity Audio player ready...
By LAURAN NEERGAARD, AP Medical Writer
Leading U.S. medical groups are urging people to get updated flu and COVID-19 vaccinations this fall, banding together Wednesday to issue shot guidelines — an... |
| 11.05.2026 | Hantavirus cases spark brief surge in pharma and biotech stocks — here’s why trading is so volatile | Several pharmaceutical stocks have surged in wake of a hantavirus outbreak as investors gauge whether they could benefit from developing vaccines.
Moderna, Inovio, and Novavax surged in early trading Monday, but couldn’t sustain some of the... |
| 08.04.2026 | We’re exiting our position in a drug stock and initiating a stake in a more attractive rival | - |
| 10.03.2026 | Equatorial Guinea's High-Tech Push to End Malaria By 2030 | In the humid equatorial belt of Central Africa; where dense forests, heavy rains and winding rivers create ideal breeding grounds for mosquitoes, malaria has long been a stubborn public health adversary. For Equatorial Guinea, the disease h... |
| 27.02.2026 | There’s a ‘bearish-to-bullish’ reversal happening in this mid-cap biotech stock, says Carter Worth | - |
| 15.01.2026 | This pharma stock just got whacked — there’s still a major catalyst ahead | - |
| 30.12.2025 | Novavax COVID-19 vaccine available at some GP clinics until May 31 | Listen
3 min
New: You can now listen to articles.
This audio is generated by an AI tool.
SINGAPORE: The JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered at selected general practitioner (GP) clinics under the national vaccination pro... |
| 19.09.2025 | Kennedy’s vaccine advisers change COVID shot guidance, calling them an individual choice | By MIKE STOBBE and LAURAN NEERGAARD
ATLANTA (AP) — Health Secretary Robert F. Kennedy Jr.’s new vaccine advisers added confusion Friday to this fall’s COVID-19 vaccinations — declining to recommend them for anyone and leaving the choice up ... |
| 12.09.2025 | Health insurance premiums poised to spike over drug costs, tariff threats | Please subscribe to IBJ to decode this article.
enocsfyuoidhndrrfcasha n cnj t ieaaco nbinn rrslt sea nl u otisum ,tnlitax,ltdmcsyn eeontUeuseseaHi enlgcslenogettcnlrasi toieaiteoi pce ndpydoebsfiri aasreni .vdtoreal Aueieaelpbenutr a gSa t... |
| 12.09.2025 | Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots | Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children.
The report comes as Health and Human Services Secretary Robert F. Kennedy Jr., a... |
| 28.08.2025 | US FDA narrows COVID-19 vaccine eligibility for under-65s, keeps full access for seniors | WASHINGTON: The US Food and Drug Administration (FDA) on Wednesday (Aug 27) approved updated COVID-19 vaccines for everyone aged 65 and over but narrowed access for younger people to those with health risks, a shift from previous years when... |
| 27.08.2025 | FDA approves updated Pfizer COVID shots but limits access for some kids and adults | The new restrictions — previewed by FDA officials in May — are a break from the previous U.S. policy, which recommended an annual COVID-19 shot for all Americans 6 months and up.
This photo provided by Pfizer in August 2025 shows boxes for ... |
| 27.08.2025 | FDA approves new Covid shots with limits on who can get them under RFK Jr. | The Food and Drug Administration on Wednesday approved the latest round of Covid vaccines in the U.S., but only for those at higher risk of getting severely sick from the virus.
Health and Human Services Secretary Robert F. Kennedy Jr. said... |
| 19.08.2025 | S&P 500 falls for a fourth day, Nasdaq posts back-to-back losses as tech names slide: Live updates | The S&P 500 and Nasdaq Composite dipped on Wednesday, pressured by a broad decline in tech. Investors also weighed mixed retail earnings results and the Federal Reserve’s latest meeting minutes release.
The broad market index slipped 0.... |
| 12.08.2025 | Sorting out COVID vaccine confusion: New and conflicting federal policies raise questions | With so much in flux, it’s important to check with your employer or insurer about coverage policies before you roll up your sleeve.
Here’s what we know so far, and what remains unclear.
Q: How have the recommendations changed?
What used to ... |
| 12.08.2025 | FDA may pull authorization of Pfizer’s Covid vaccine for children under 5, company says | The Food and Drug Administration is considering revoking its authorization of Pfizer’s Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC.
The move could leave many kids with no available shots against... |
| 11.08.2025 | Ousted FDA vaccine chief Vinay Prasad is returning to the agency | But Prasad has had the backing of FDA Commissioner Marty Makary and health secretary Robert F. Kennedy Jr., who have both called for scrutinizing the use of COVID-19 vaccines. Under Prasad, the FDA restricted the approval of two new COVID-1... |
| 02.07.2025 | FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff | Related Articles
New CIA report criticizes investigation into Russia’s support for Trump in 2016
Trump to meet at White House with American hostage freed from Gaza
Florida’s ‘Alligator Alcatraz’ detention center is set to receive its first ... |
| 01.07.2025 | The Future of Vaccines and Antibodies: A New Era in Medicine | In the world of medicine, innovation is the lifeblood that keeps the industry vibrant. Two recent breakthroughs showcase the power of science and technology in fighting diseases: Moderna's promising flu vaccine and Chai Discovery's revoluti... |
| 01.07.2025 | The Future of Vaccines and Drug Discovery: A New Era in Healthcare | In the ever-evolving landscape of healthcare, two recent developments stand out: Moderna's promising flu vaccine and the collaboration between XtalPi and Pfizer in drug discovery. Both stories reflect a shift towards innovation, driven by t... |
| 30.06.2025 | Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot | Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial.
The positive data pave the way for Moderna to apply for approval of its standalone... |
| 27.06.2025 | RFK Jr.’s made promises about vaccines. Here’s what he’s done as health secretary | Here’s a look at what Kennedy has said and done since becoming the nation’s top health official on Feb. 13. Kennedy and the childhood vaccine schedule
Sen. Bill Cassidy, a physician who was unsettled about Kennedy’s antivaccine work, said K... |
| 22.05.2025 | FDA panel is split on updates to COVID shots as questions loom for fall vaccinations | Other panelists noted that subtype is such a close relative that last year’s shots seem to offer cross-protection, at least for now but with no guarantee there wouldn’t be a different version circulating by the time a vaccination campaign r... |
| 21.05.2025 | Navigating the FDA Landscape: Insights from John Emmert's Inspections and the Vaccine Debate | In the intricate world of food and drug safety, the FDA stands as a sentinel. Its inspectors, like John Emmert, wield significant influence over public health. With over 600 inspections under his belt, Emmert's work sheds light on complianc... |
| 20.05.2025 | New Trump vaccine policy limits access to COVID shots | It’s unclear what the upcoming changes mean for people who may still want a fall COVID-19 shot but don’t clearly fit into one of the categories.
“Is the pharmacist going to determine if you’re in a high-risk group?” asked Dr. Paul Offit, a ... |
| 19.05.2025 | RFK Jr. pledged not to upend US vaccine system, but big changes are underway | “I think you have to assume that RFK Jr.’s intention is to make it harder for vaccines to come to market,” said Dr. Amesh Adalja, a vaccine expert at Johns Hopkins University. The changes are “looked at suspiciously because this is someone ... |
| 19.05.2025 | Stocks, bonds and the dollar drift after the latest downgrade to the US government’s credit rating | Stocks and U.S. government bond prices at first fell sharply early in Monday’s trading, but they trimmed their losses as the day progressed. The S&P 500 went from a loss of 1.1% to a modest gain of 0.2% before drifting through the after... |
| 19.05.2025 | Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine | Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine
By ReutersMay 19, 202511:34 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 A box with the "Nuvaxovid... |
| 14.05.2025 | Novavax's Path to Approval: A Vaccine's Journey Through Regulatory Hurdles | In the ever-evolving landscape of healthcare, Novavax is navigating a stormy sea. The company, known for its COVID-19 vaccine, is in talks with the FDA, seeking full approval. This dialogue is crucial. It’s the lifeline that could transform... |
| 09.05.2025 | Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears | Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears
By Sriparna RoyMay 8, 20259:34 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A woman holds a small bottle l... |
| 28.04.2025 | FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots | Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking office, he’s promised to “investigate” children’s shots, canceled meetings of expert vaccine advisers and directed o... |
| 26.04.2025 | The Vaccine Tug-of-War: Novavax's Path to Approval Amidst Political Storms | In the world of vaccines, the stakes are high. Novavax, a player in the COVID-19 vaccine arena, is navigating a turbulent sea. The company recently announced that its COVID-19 shot is on track for full approval from the FDA. But the journey... |
| 23.04.2025 | Novavax says its COVID-19 shot is on track for full FDA approval after delay | But FDA’s acting commissioner, Dr. Sara Brenner, directed the agency’s lead official overseeing the vaccine to pause the decision, according to one of the people. The delay, first reported by The Wall Street Journal, sparked concerns of pol... |
| 01.04.2025 | RFK Jr. is a ‘conspiracy theorist’ endangering lives, say analysts at Howard Lutnick’s former firm | Health and Human Services Secretary Robert F. Kennedy Jr., an anti-vaccine crusader, is not qualified to have any power at the agency that’s supposed to protect the health of Americans, said research analysts at Cantor Fitzgerald, which was... |
| 31.03.2025 | Vaccine stocks fall after key FDA official resigns in protest of RFK Jr. | Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks.
Marks stepped down in protest of Health and Human Services Secretary Robert F. Kennedy’... |
| 22.03.2025 | America needs a jab in its corporate backside | - |
| 20.02.2025 | JPMorgan’s top biopharma picks for 2025 | - |
| 24.01.2025 | Navigating Health in a Digital Age: Singapore's Bold Moves | In a world where screens dominate our lives, Singapore is taking a stand. The nation is rolling out new guidelines aimed at curbing excessive screen time among children. This initiative is part of a broader health strategy called Grow Well ... |
| 23.01.2025 | Updated Novavax COVID-19 vaccine available at some GP clinics until Apr 30 | Listen
2 min
New: You can now listen to articles.
This audio is generated by an AI tool.
SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at selected Healthier SG genera... |
| 02.01.2025 | Health | 5 things we know and still don’t know about COVID, 5 years after it appeared | It’s a difficult scientific puzzle to crack in the best of circumstances. The effort has been made even more challenging by political sniping around the virus’ origins and by what international researchers say are moves by China to withhold... |
| 03.12.2024 | Novavax XBB1.5 COVID-19 vaccine will cease to be offered from Jan 1, 2025 | Listen to this article
Novavax XBB1.5 COVID-19 vaccine will cease to be offered from Jan 1, 2025
1 min
New: You can now listen to articles.
This audio is generated by an AI tool.
SINGAPORE: The Novavax/Nuvaxovid XBB1.5 COVID-19 vaccine will... |
| 15.11.2024 | Market Pulse: The Fed's Caution and Its Ripple Effects | The financial landscape is a shifting terrain, and recent comments from Federal Reserve Chair Jerome Powell have sent tremors through the market. Futures took a dive as Powell signaled a cautious approach to interest rate cuts. This decisio... |
| 15.11.2024 | Market Whirlwinds: The Dance of Rates and Stocks | The financial landscape is a tempest. Futures are falling, and the winds of change are blowing from the Federal Reserve. On November 15, 2024, the stock market felt the tremors of Jerome Powell's cautious words. The Fed Chair's message was ... |
| 15.11.2024 | Futures drop as Powell signals no hurry on rate cuts | Futures drop as Powell signals no hurry on rate cuts
By ReutersNovember 15, 202410:58 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The Nasdaq Market site is seen outside the Nasdaq Market sit... |
| 12.11.2024 | Wall Street muted as focus moves to economic data | U.S. MarketsWall Street muted as focus moves to economic data
By Lisa Pauline Mattackal and Purvi AgarwalNovember 12, 20243:16 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A trader works at t... |
| 10.09.2024 | Health | When should I get flu and COVID shots? Experts disagree — but say get them however you can | Ideally, people would get their shots around late October, since the flu typically takes off in the state near the end of the year, Guthmiller said.
Not everyone agrees that waiting is the best plan.
While some people like to time their sho... |
| 06.09.2024 | Weekly Recap: 10 Health Press Releases You Might Have Missed | A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a new COVID-19 vaccine, Prostate Cancer Awareness Month news and Walk to End Alzheimer's.
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- With thousand... |
| 05.09.2024 | Cordlife's Recovery: Lessons from a Crisis | In the world of healthcare, trust is paramount. When that trust is shaken, the path to recovery can be steep. Cordlife, Singapore's oldest private cord blood bank, recently faced a significant crisis. A mishandling incident led to the suspe... |
| 05.09.2024 | Singapore's Health Strategy: Navigating the Mpox Challenge and Vaccine Changes | In the heart of Southeast Asia, Singapore stands as a beacon of public health management. Recently, the nation has been thrust into the spotlight due to the emergence of mpox, a viral disease that has raised alarms globally. As the World He... |
| 31.08.2024 | Dow notches record high close after upbeat economic data | U.S. MarketsDow notches record high close after upbeat economic data
By Noel RandewichAugust 30, 20249:04 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
SummaryCompanies
Economic data supports ... |
| 30.08.2024 | Sinovac COVID-19 vaccine will cease to be offered after September: MOH | Listen to this article
Sinovac COVID-19 vaccine will cease to be offered after September: MOH
1 min
New: You can now listen to articles.
This audio is generated by an AI tool.
SINGAPORE: Singapore's national vaccination programme will stop ... |
| 30.08.2024 | FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants | SILVER SPRING, Md., Aug. 30, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating ... |
| 29.08.2024 | Endo's Financial Turnaround: A New Chapter in Pharmaceuticals | Endo, Inc. is navigating a stormy sea, but recent financial results suggest it may be charting a course toward calmer waters. The company, based in Malvern, Pennsylvania, has released its second-quarter financial results for 2024, revealing... |
| 29.08.2024 | Navigating the New Normal: COVID Vaccines and Creative Leadership in Healthcare | The landscape of healthcare marketing is shifting. Imre, a prominent brand engagement agency, has made significant strides by appointing Tracy Zuto and Malia Baker as key creative leaders. Their arrival signals a commitment to innovative, i... |
| 27.08.2024 | ENDO REPORTS SECOND-QUARTER 2024 FINANCIAL RESULTS | Raises 2024 Financial Expectations
Provides 2025 Financial Expectations
MALVERN, Pa., Aug. 27, 2024 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI), a diversified specialty pharmaceutical company trans... |
| 27.08.2024 | Health | The new COVID vaccine is out. Why you might not want to rush to get it. | The Centers for Disease Control and Prevention now looks to wastewater as fewer people are reporting test results to health authorities. The wastewater data shows the epidemic is worst in Western and Southern states. In New York, for exampl... |
| 09.08.2024 | Weekly Recap: 12 Press Releases You Might Have Missed | A roundup of the most newsworthy press releases from PR Newswire this week, including the Fortune Global 500, new collectibles from McDonald's and new eco-friendly disinfecting wipes from Clorox.
NEW YORK, Aug. 9, 2024 /PRNewswire/ -- With ... |
| 08.08.2024 | Gilead quarterly profit beats Street estimates, revenue up 5% | Healthcare & PharmaceuticalsCommercial Strategy
Gilead quarterly profit beats Street estimates, revenue up 5%
By Deena BeasleyAugust 8, 20248:05 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Li... |
| 08.08.2024 | Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights | Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash
Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccine
Received $570 million in upf... |
| 24.06.2024 | mRNA influenza vaccines – VacZine Analytics forecast a third of global market value in 2030 | This month VacZine Analytics, a specialist in infectious diseases and vaccines commercial analysis publishes a brand-new global analysis of the seasonal influenza vaccine market including mRNA products (monovalent and combinations)
Annual s... |
| 21.06.2024 | Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine | Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
Fri, Jun 21, 2024 11:30 CET Report this content
Hørsholm, Denmark, 21 June 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechn... |
| 19.06.2024 | Future pandemic response should not be about 'fighting last war': Ong Ye Kung | Listen to this article
Future pandemic response should not be about 'fighting last war': Ong Ye Kung
1 min
New: You can now listen to articles.
This audio is generated by an AI tool.
SINGAPORE: There is a tendency for governments to prepare... |
| 06.06.2024 | Updated COVID-19 vaccine in coming months should target variants with JN.1 lineage, say US advisers | Advisers to the US Food and Drug Administration on Wednesday (Jun 5) unanimously voted in favour of recommending that COVID-19 vaccines for 2024-25 should target a strain within the lineage of the JN.1 variant that has been dominant this ye... |
| 02.06.2024 | WHO members approve steps to bolster health regulations for pandemics | - |
| 28.05.2024 | Updated Novavax COVID-19 vaccine available free under Singapore's national vaccination programme | Listen to this article
Updated Novavax COVID-19 vaccine available free under Singapore's national vaccination programme
1 min
New: You can now listen to articles.
Sorry, the audio is unavailable right now. Please try again later.
This audio... |
| 25.05.2024 | Efforts to draft pandemic treaty falter as countries disagree on steps | - |
| 23.05.2024 | Health | Could current COVID vaccines protect against future outbreaks? New study offers hope | What is immune imprinting?
Researchers from Washington University’s School of Medicine in St. Louis evaluated the ability of the COVID-19 shots to build up memory in the immune system through a process called immune imprinting.
“Immune impr... |
| 13.05.2024 | Novavax to Participate in BofA Securities 2024 Health Care Conference | GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Confere... |
| 10.05.2024 | "FLiRT" COVID variants are now more than a third of U.S. cases. Scientists share what we know about them so far. | More than a third of COVID-19 cases in the U.S. are now estimated to be from a new, fast-growing member of a group of so-called "FLiRT" variants, nicknamed for their small but distinctive changes relative to the JN.1 strain. JN.1 ... |
| 10.05.2024 | French, US drug firms team up for COVID-flu shot | PARIS: French pharmaceutical giant Sanofi and struggling US rival Novavax announced on Friday (May 10) an alliance to sell a COVID-19 vaccine and develop another that combines with a flu shot.
Under a licensing deal worth up to US$1.2 billi... |
| 10.05.2024 | US equity funds gain weekly inflows amid renewed hopes of rate cut | U.S. MarketsUS equity funds gain weekly inflows amid renewed hopes of rate cut
By ReutersMay 10, 20242:14 PM UTCUpdated ago
Save
Text
Small Text
Medium Text
Large Text
Share
Twitter
Facebook
Linkedin
Email
Link
People walk by the New York S... |
| 10.05.2024 | Nations struggle to draft pandemic treaty to avoid mistakes made in Covid | - |
| 10.05.2024 | Novavax strikes $1.2 billion deal with Sanofi in major turnaround | figcaption>span]:font-sans">
The French drug giant Sanofi is taking a minority stake in Novavax and entering into a licensing agreement worth as much as $1.2 billion that includes selling a combination COVID-flu shot.
Why it matt... |
| 10.05.2024 | Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines | Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards
Provides Novavax with cash and an equity investment totalling approximately $... |
| 10.05.2024 | Novavax Reports First Quarter 2024 Financial Results and Operational Highlights | Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvant
This agreement repr... |
| 10.05.2024 | Novavax signs Covid-19 license deal with Sanofi, secures business viability | - |
| 17.04.2024 | Путин: в мире высок риск возникновения новых эпидемий, особенно уязвима Африка | - |
| 16.04.2024 | Biden govt announces partnership with 50 nations to stifle future pandemics | - |
| 04.04.2024 | Don't count us out yet, Novavax says | After losing out on the COVID-19 vaccine race, Novavax is hoping its experimental combo flu-COVID vaccine can help turn around its fortunes.
But it finds itself in a familiar position of playing catch-up.
Why it matters: A year after it war... |
| 01.02.2024 | Novavax is on thin ice, and the latest update isn’t exactly encouraging | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with the latest twist in biotech’s recovery, a close look at Bluebird Bio, and the unce... |
| 28.11.2023 | Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization | GAITHERSBURG, Md., Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been gr... |
| 18.10.2023 | Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore | GAITHERSBURG, Md., Oct. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Singapore's Health Sciences Authority (HSA) has granted full ... |
| 04.10.2023 | Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. | This Emergency Use Authorization and CDC recommendation makes Novavax's vaccine the only protein-based non-mRNA COVID vaccine option in the U.S.
Novavax expects doses will be available in thousands of locations across the U.S. in the coming... |
| 11.09.2023 | FDA Approves Updated Covid-19 Vaccines to Address Now Circulating Variants | Two updated Covid-19 vaccines based on messenger RNA technology now have the FDA’s regulatory nod, setting the stage for the new shots to become available soon as the fall respiratory illness season approaches.
Covid-19 vaccines from partne... |
| 09.08.2023 | New COVID vaccine and booster shots for this fall to be available by end of September | The first new COVID-19 vaccines updated for this fall season are now expected to be available by the end of September, once both the Food and Drug Administration and the Centers for Disease Control and Prevention sign off on the new shots. ... |
| 16.06.2023 | Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall | Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaign
Novavax shared data demonstrating that its XBB.1.... |
| 12.05.2023 | Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore | GAITHERSBURG, Md., May 12, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has grante... |
| 09.05.2023 | Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses | This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID
Preliminary topline immune responses for all three vaccine candidates were robust versus authorized comparator... |
| 19.04.2023 | Many seniors now eligible to get another COVID booster, CDC says | Many seniors can now get another COVID-19 vaccine booster, after the Centers for Disease Control and Prevention greenlighted a broad swath of changes on Wednesday that were first authorized by the Food and Drug Administration the day before... |
| 18.04.2023 | FDA clears second bivalent COVID boosters for some Americans | Some Americans will soon be able to get another shot of the bivalent COVID-19 vaccines, the Food and Drug Administration authorized Tuesday, including seniors ages 65 and older and people with compromised immune systems.
Seniors can get the... |
| 13.03.2023 | What research shows about risks of myocarditis from COVID vaccines versus risks of heart damage from COVID | Frank Han is an assistant professor of pediatric cardiology at the University of Illinois at Chicago and Jennifer H. Huang is an associate professor of pediatric cardiology at Oregon Health & Science University.
Soon after the first COV... |
| 01.03.2023 | Novavax stock plunges 25% after the COVID-19 vaccine maker warns it could go out of business | Novavax shares sank 25% after it said it has "substantial doubt" about its ability to stay in business.
The biotech plans spending cuts after it fourth-quarter loss was twice as deep as analysts expected.
Advertisement
Novavax sha... |
| 13.02.2023 | U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine | Modified agreement also includes the development of an updated vaccine in fall 2023
GAITHERSBURG, Md., Feb. 13, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-gene... |
| 18.01.2023 | Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster | GAITHERSBURG, Md., Jan. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bio... |
| 09.01.2023 | COVID-19 vaccines: From nasal drops to a redesign, what 2023 could have in store | Several vaccine companies say they are expecting breakthroughs as early as this year as they pursue new ways to protect people against SARS-CoV-2, the virus that causes COVID-19.
The Food and Drug Administration is set to convene a panel of... |
| 03.01.2023 | Digital health news, funding round up in the prior week; January 3, 2023 | Gold Kidney raised $60M; BioRegenx and Findit merged; DOJ filed a lawsuit against AmerisourceBergen
Top Health News
Quantori, a provider of data science and digital transformation solutions for life science and healthcare organizations, ann... |
| 30.12.2022 | Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates | GAITHERSBURG, Md., Dec. 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a... |
| 28.12.2022 | Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock | GAITHERSBURG, Md., Dec. 28, 2022 /PRNewswire/ -- On December 20, 2022, Novavax, Inc. NVAX, a biotechnology company (the "Company" or "Novavax") dedicated to developing and commercializing next-generation vaccines for ser... |
| 16.12.2022 | Novavax Announces Pricing of $65 Million Public Offering of Common Stock | GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an u... |
| 16.12.2022 | Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes | GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an o... |
